Health
Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward – TCTMD
DREAM-HF provides hints of an anti-inflammatory effect and benefits beyond the heart, setting up future trials.
Targeted injection of mesenchymal precursor cells (MPCs) into the myocardium is safe but does not reduce recurrent nonfatal decompensated heart failure (HF) events in patients with chronic HF with reduced ejection fraction (HFrEF), the randomized DREAM-HF…
Continue Reading
-
General21 hours agoIsraeli forces open fire towards diplomatic delegation touring Jenin in the northern West Bank
-
General18 hours agoRegional house price growth outstrips capital cities
-
General14 hours agoCharlotte McConaghy calls for climate change action in new novel Wild Dark Shore
-
General16 hours agoChina says Donald Trump’s Golden Dome plans risk weaponising space